Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
- The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
- The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
- Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
- A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”